Evidence map›Paper›PMID 26078357›Full record

ArticleStatistical methods in medical research2017

Accounting for dropout reason in longitudinal studies with nonignorable dropout.

Camille M Moore, Samantha MaWhinney, Jeri E Forster, Nichole E Carlson, Amanda Allshouse, Xinshuo Wang, Jean-Pierre Routy, Brian Conway, Elizabeth Connick

Open access · greenAbstract read
In one paragraph

Article in Statistical methods in medical research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact, top 84% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 13 citations in OpenAlex.

  1. Refining the Parkinson's Disease Risk Estimator for Decline In Cognition Tool (PREDICT).Cognitive and behavioral neurology : official journal of the Society for Behavioral and Cognitive Neurology · 2026
    Article
  2. Article
  3. Sample size matters: A step-by-step guide for radiologists.Journal of clinical imaging science · 2025
    Review
  4. Sample size determination: A practical guide for health researchers.Journal of general and family medicine · 2023
    Review
  5. Article
  6. Article
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 2 countries.

Camille M Moore1 Department of Biostatistics and Informatics, Colorado School of Public Health, University of Colorado Denver, Aurora, CO, USA.
Samantha MaWhinney1 Department of Biostatistics and Informatics, Colorado School of Public Health, University of Colorado Denver, Aurora, CO, USA.
Jeri E Forster1 Department of Biostatistics and Informatics, Colorado School of Public Health, University of Colorado Denver, Aurora, CO, USA.
Nichole E Carlson1 Department of Biostatistics and Informatics, Colorado School of Public Health, University of Colorado Denver, Aurora, CO, USA.
Amanda Allshouse1 Department of Biostatistics and Informatics, Colorado School of Public Health, University of Colorado Denver, Aurora, CO, USA.
Xinshuo Wang1 Department of Biostatistics and Informatics, Colorado School of Public Health, University of Colorado Denver, Aurora, CO, USA.
Jean-Pierre Routy4 Division of Hematology and Chronic Viral Illness Service, McGill University, Montreal, Quebec, Canada.
Brian Conway5 Vancouver Infectious Diseases Centre, Vancouver, British Columbia, Canada.
Elizabeth Connick6 Division of Infectious Diseases, University of Colorado Denver, Aurora, CO, USA.
University of Colorado Denver · USColorado School of Public Health · USMcGill University · CAVancouver Infectious Diseases Centre · CA

Funding

Southern California Primary Infection ProgramU01AI043638 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI RICHMAN, DOUGLAS D · 1998 to 2010
$21.3M
Viral Determinants of HIV-1 Transmission in African HeterosexualsP01AI057005 · NIAID · UNIVERSITY OF WASHINGTON · PI COREY, LAWRENCE · 2003 to 2014
$20.5M
IMMUNOLOGIC &VIROLOGIC FEATURES OF EARLY HIV INFECTIONU01AI041531 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI LEVY, JAY A · 1997 to 2006
$13.0M
PATHOGENESIS AND TREATMENT OF ACUTE HIV INFECTIONU01AI052403 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI WALKER, BRUCE D · 2002 to 2006
$10.5M
VIRAL AND IMMUNE CONSEQUENCES OF EARLY HIV1 THERAPYU01AI041534 · NIAID · AARON DIAMOND AIDS RESEARCH CENTER · PI MARKOWITZ, MARTIN H · 1997 to 2006
$10.1M
UAB AIEDRP: Immune Control and Escape in Acute InfectionU01AI041530 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI KILBY, JOHN MICHAEL · 1997 to 2006
$7.0M
ACUTE INFECTION AND EARLY DISEASE RESEARCH NETWORKU01AI041532 · NIAID · JOHNS HOPKINS UNIVERSITY · PI MARGOLICK, JOSEPH B. · 1997 to 2003
$3.3M
IMMUNOPATHOGENESIS OF ACUTE HIV-1 INFECTIONU01AI041536 · NIAID · UNIVERSITY OF COLORADO DENVER · PI SCHOOLEY, ROBERT TURNER · 1997 to 2002
$2.9M
Sex, Drugs and Consequences of Dropout on HIV Outcomes in WIHS, MACS, and AIEDRPR01DA030495 · NIDA · UNIVERSITY OF COLORADO DENVER · PI FORSTER, JERI E, MAWHINNEY-DELSON, SAMANTHA · 2010 to 2012
$688k
Consequences of drug use and informative dropout on HIV/AIDS outcomes in the MACSR03DA026743 · NIDA · UNIVERSITY OF COLORADO DENVER · PI FORSTER, JERI E, MAWHINNEY-DELSON, SAMANTHA · 2009 to 2010
$308k
Bayesian Methods for Nonignorable Dropout in HIV Outcomes & Drug Abuse ResearchR36DA037778 · NIDA · UNIVERSITY OF COLORADO DENVER · PI MOORE, CAMILLE M. · 2014 to 2015
$106k
NIAID NIH HHS P01 AI057005NIAID NIH HHS U01 AI041530NIAID NIH HHS U01 AI041531NIAID NIH HHS U01 AI041532NIAID NIH HHS U01 AI041534NIAID NIH HHS U01 AI041536NIAID NIH HHS U01 AI043638NIAID NIH HHS U01 AI052403NIDA NIH HHS R01 DA030495NIDA NIH HHS R03 DA026743NIDA NIH HHS R36 DA037778
6 · The paper itself

Abstract

Dropout is a common problem in longitudinal cohort studies and clinical trials, often raising concerns of nonignorable dropout. Selection, frailty, and mixture models have been proposed to account for potentially nonignorable missingness by relating the longitudinal outcome to time of dropout. In addition, many longitudinal studies encounter multiple types of missing data or reasons for dropout, such as loss to follow-up, disease progression, treatment modifications and death. When clinically distinct dropout reasons are present, it may be preferable to control for both dropout reason and time to gain additional clinical insights. This may be especially interesting when the dropout reason and dropout times differ by the primary exposure variable. We extend a semi-parametric varying-coefficient method for nonignorable dropout to accommodate dropout reason. We apply our method to untreated HIV-infected subjects recruited to the Acute Infection and Early Disease Research Program HIV cohort and compare longitudinal CD4

Indexed as

Longitudinal StudiesAdultCD4 Lymphocyte CountCD4-Positive T-LymphocytesDisease ProgressionDrug UsersFollow-Up StudiesHIV InfectionsHumansMaleModels, StatisticalPatient DropoutsSubstance Abuse, IntravenousTime FactorsB-splinedropoutHIV/AIDSlongitudinal datanonignorable missing datavarying-coefficient model

Identifiers

PMID26078357
PMCPMC4679750
OpenAlexW2373287088

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.